Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences
May 16, 2022 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, May 16, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is excited to announce...
WPD Pharmaceuticals Signs Consortium Agreement on EuroNanoMed Project
March 07, 2022 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, March 07, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is excited to...
WPD Pharmaceuticals Announces Proposed Restructuring of Polish Subsidiary
February 09, 2022 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1) announces that the Company’s board of directors (the “Board”)...
WPD Pharmaceuticals Announces Appointment of New Director
February 03, 2022 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 03, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), is pleased to announce that the Company appointed Mr....
WPD Pharmaceuticals Secures Berubicin Sub-License Rights in Perpetuity
February 01, 2022 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 01, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), announced that in respect to its sublicense agreement with...
WPD Pharmaceuticals Enters into Amended and Restated Sublicense Agreement with Moleculin Biotech
January 25, 2022 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), is pleased to announce that it has entered into an amended...
WPD Pharmaceuticals Signs Agreement with NCRD for $6.3M Grant for the Development of Liposomal Annamycin, Intended as a Treatment for AML
December 16, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Dec. 16, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...
WPD Pharmaceuticals Announces AGSM Results
October 01, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Oct. 01, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, announces the results...
WPD Pharmaceuticals Announces AGM September 29; Plans Different Path to Fundraising Through Delisting; WPD Poland Arranges Additional Loans; Communications Consultant in Poland
September 02, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Sept. 02, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, announces that it...
WPD Pharmaceuticals’ Licensor Receives FDA Fast Track Designation for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans
July 12, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...